Targeting HER (ERBB) signaling in head and neck cancer: An essential update

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Head and neck cancer (HNC) is a significant global health concern, ranking as the 6th most common carcinoma.
• Conventional treatments for HNC often result in suboptimal survival rates and significant toxicities.
• Targeted therapies, particularly those inhibiting the epidermal growth factor receptor (EGFR), have shown limited success in HNC clinical settings, necessitating novel strategies.

Purpose of the Study:

• To review the emerging roles of human epidermal growth factor receptor (HER) family members beyond EGFR in HNC.
• To provide a comprehensive update on HER signaling pathways in HNC, addressing resistance mechanisms.
• To explore novel therapeutic strategies targeting the HER network in HNC.

Main Methods:

• Literature review focusing on recent advancements in HER signaling research relevant to HNC.
• Analysis of EGFR nuclear translocation and receptor spatial regulation.
• Examination of the interdependence and interactions among different HER family members.

Main Results:

• EGFR-targeted therapy has yielded suboptimal outcomes in HNC, highlighting the need for alternative approaches.
• Emerging evidence suggests critical roles for other HER family members in HNC development and progression.
• Understanding the complex interplay within the HER network is crucial for developing effective treatments.

Conclusions:

• The HER signaling network in HNC is complex, involving multiple receptor members and regulatory mechanisms.
• Overcoming resistance to current targeted therapies requires a broader understanding of the entire HER family.
• Future therapeutic strategies should consider targeting multiple HER members or novel aspects of their signaling pathways to improve HNC outcomes.